These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 38550492)
1. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor. Meher BR; Mohanty RR; Dash A Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672 [TBL] [Abstract][Full Text] [Related]
2. Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder. Nakashima S; Hao A; Uchio N; Matsumoto H Cureus; 2024 Feb; 16(2):e55010. PubMed ID: 38550492 [TBL] [Abstract][Full Text] [Related]
3. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders. Paton DM Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218 [TBL] [Abstract][Full Text] [Related]
4. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Fung S; Shirley M CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107 [TBL] [Abstract][Full Text] [Related]
5. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report. Li X; Wu W; Zeng Y; Wu W; Hou C; Zhu H; Liao Y; Tian Y; Chen Z; Peng B; Chen WX Front Immunol; 2023; 14():1257955. PubMed ID: 37915570 [TBL] [Abstract][Full Text] [Related]
6. [Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder]. Prakhova LN; Krasnov VS; Kasatkin DS; Korobko DS Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7. Vyp. 2):68-72. PubMed ID: 35912559 [TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report. Yoshida T; Watanabe O; Nomura M; Yoshimoto Y; Maki Y; Takashima H Front Neurol; 2023; 14():1322412. PubMed ID: 38162440 [TBL] [Abstract][Full Text] [Related]
8. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series. Yamamura T; Araki M; Fujihara K; Okuno T; Misu T; Guo YC; Hemingway C; Matsushima J; Sugaya N; Yamashita M; von Büdingen HC; Miyamoto K Mult Scler Relat Disord; 2022 May; 61():103772. PubMed ID: 35537314 [TBL] [Abstract][Full Text] [Related]
9. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Takai Y; Kuroda H; Misu T; Akaishi T; Nakashima I; Takahashi T; Nishiyama S; Fujihara K; Aoki M Mult Scler Relat Disord; 2021 Apr; 49():102750. PubMed ID: 33524925 [TBL] [Abstract][Full Text] [Related]